<div id="readability-page-1"><p>Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have been given an average rating of &#34;Moderate Buy&#34; by the six research firms that are  covering the company, MarketBeat.com reports. One research analyst  has rated the stock with a sell recommendation, one  has given a hold recommendation and four have given a buy recommendation to  the company. The average 1 year price target among analysts that have covered the stock in the last year is $32.50.</p><p>Several brokerages have recently issued reports on BDSX. Weiss Ratings  reissued a &#34;sell (e+)&#34; rating on shares of Biodesix in a research note on Monday, December 22nd. Wall Street Zen upgraded Biodesix from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 8th.</p><p><b>View Our Latest Report on Biodesix</b></p><h2>Biodesix Price Performance</h2><p>Biodesix stock opened at $9.93 on Tuesday. Biodesix has a 1 year low of $3.44 and a 1 year high of $20.40. The company has a debt-to-equity ratio of 41.11, a quick ratio of 1.84 and a current ratio of 1.84. The firm has a 50 day moving average price of $8.25 and a 200 day moving average price of $7.94. The company has a market cap of $79.04 million, a price-to-earnings ratio of -1.79 and a beta of 0.66. </p><h2>Insider Buying and Selling at Biodesix</h2><p>In other news, Director Jack W. Schuler acquired 82,465 shares of Biodesix stock in a transaction dated Thursday, January 22nd. The shares were acquired at an average cost of $10.96 per share, with a total value of $903,816.40. Following the purchase, the director directly owned 1,463,210 shares of the company's stock, valued at approximately $16,036,781.60. This trade represents a 5.97% increase in their position. The acquisition was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this link. Over the last quarter, insiders bought 182,465 shares of company stock valued at $2,084,616 and sold 1,947 shares valued at $15,868. 30.10% of the stock is owned by corporate insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Hedge funds have recently bought and sold shares of the business. Aberdeen Group plc purchased a new stake in  Biodesix during the fourth quarter worth approximately $1,784,000.  XTX Topco Ltd lifted its holdings in shares of  Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company's stock valued at $58,000 after acquiring an additional 102,494 shares in the last quarter.  Geode Capital Management LLC boosted its position in  Biodesix by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company's stock worth $289,000 after purchasing an additional 2,235 shares during the period.  Oracle Investment Management Inc. purchased a new stake in  Biodesix during the 3rd quarter worth $113,000.  Finally, Millennium Management LLC acquired a new stake in  Biodesix in the 3rd quarter valued at $113,000. Hedge funds and other institutional investors own  20.96% of the company's stock. </p><h2>Biodesix Company Profile</h2> (Get Free Report)<p>Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.  </p><p>The company's flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Biodesix</li><li>The buying spree that no one is talking about</li><li>How to collect $500-$800 weekly (BlackRock's system)</li><li>Trump’s AI Secret: 100X Faster Than Nvidia</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>They just tried to kill gold</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Biodesix Right Now?</h2><p>Before you consider Biodesix, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biodesix wasn't on the list.</p><p>While Biodesix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IDNA

BDSX

ARKG

SBIO

<p>Biodesix, Inc. (NASDAQ:BDSX) has received an average rating of "Moderate Buy" from six research firms. One analyst rated it as a sell, one as hold, and four as buy. The average one-year price target is $32.50. The stock opened at $9.93, with a 1-year low of $3.44 and a high of $20.40. Insider Jack W. Schuler acquired 82,465 shares at $10.96 each. Hedge funds own 20.96% of the stock. Biodesix specializes in blood-based tests for lung diseases and operates a CLIA-certified laboratory.</p>

Market Beat

Invesco Biotechnology & Genome ETF

iShares Genomics Immunology and Healthcare ETF

VanEck Biotech ETF

SPDR S&P Biotech

iShares Biotechnology ETF

Biodesix

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Biodesix, Inc. (NASDAQ:BDSX) Receives Average Rating of "Moderate Buy" from Brokerages